Atezolizumab,Carboplatin,Etoposide,Tiragolumab
Roche
['sclc']
#asco2022 the path forward in sclc remains a "slippery slope". unfortunately skyscrper-02 shows no pfs or os benefit from adding anti-tigit to current soc. failure of this drug class or wrong tumor type for this strategy? "jury is still out" in my opinion. 
Medical Oncologist and clinical-translational researcher in lung cancer. Director-Thoracic Oncology at UC Davis Comprehensive Cancer Center